Companies › Ambrx
1 active drug program in 5 registered trials: 5 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Anvatabart Opadotin (ARX788) Tubulin inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent | Tubulin, ERBB2 | Phase 2 | HER2 Positive Metastatic Breast Cancer; Breast Neoplasms; HER2-positive, Metastatic Breast Cancer; HER2-positive Breast Cancer … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04829604 | Anvatabart Opadotin (ARX788) | Phase 2 | HER2 Positive Metastatic Breast Cancer | Oncology | Dec 2026 |
| NCT04983121 | Anvatabart Opadotin (ARX788) | Phase 2 | Breast Neoplasms | Oncology | Aug 2027 |
| NCT06663748 | Anvatabart Opadotin (ARX788) | Phase 2 | HER2-positive, Metastatic Breast Cancer | Oncology | Nov 2027 |
| NCT05426486 | Anvatabart Opadotin (ARX788) | Phase 2 | HER2-positive Breast Cancer | Oncology | Dec 2028 |
| NCT06224673 | Anvatabart Opadotin (ARX788) | Phase 2 | HER2 Low Breast Carcinoma | Oncology | Nov 2029 |
Roche Beijing Biotech Pfizer Sichuan Kelun-Biotech Biopharmaceutical Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical RemeGen Takeda AbbVie Criterium
Partner Therapeutics CrystalGenomics STCube Convergent Therapeutics I-Mab Biopharma US
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.